Evidence map›Paper›PMID 41372636›Full record

ArticleTargeted oncology2026

Translational Relevance of the Genomic Landscape of KRAS

Khalid Jazieh, Jill Tsai, Sheila Solomon, Mojun Zhu, Katrina S Pedersen, Martin E Fernandez-Zapico, Hao Xie

Abstract read
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Khalid JaziehDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55901, USA.
Jill TsaiGuardant Health, Palo Alto, CA, USA.
Sheila SolomonGuardant Health, Palo Alto, CA, USA.
Mojun ZhuDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55901, USA.
Katrina S PedersenDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55901, USA.
Martin E Fernandez-ZapicoDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55901, USA.
Hao XieDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55901, USA. xie.hao@mayo.edu.ORCID http://orcid.org/0000-0002-9640-4055

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Institutional Career Development CoreKL2TR002379 · NCATS · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2017 to 2026
$14.9M
NCATS NIH HHS KL2 TR002379NCATS NIH HHS UL1 TR002377
6 · The paper itself

Abstract

backgroundKRAS

objectiveHere, we aimed at defining the landscape of these additional genomic features of KRAS PATIENTS AND

methodsThis retrospective analysis utilized circulating tumor DNA data from two cohorts with advanced CRC and PDAC: a national cohort from Guardant (n = 27,497) and a Mayo Clinic cohort (n = 1434). Patients were categorized into three groups: KRAS

resultsAmong patients with KRAS

conclusionsWe described the genomic landscape of KRAS

Indexed as

Carcinoma, Pancreatic DuctalColorectal NeoplasmsGenomicsPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationPrognosisRetrospective StudiesKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID41372636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.